Literature DB >> 19878631

observational studies: propensity score analysis of non-randomized data.

M Trojano1, F Pellegrini, D Paolicelli, A Fuiani, V Di Renzo.   

Abstract

The randomized controlled trial (RCT) is considered to be the "gold standard" for providing evidence on drug efficacy. However, particularly for answering long-term questions in chronic diseases such as multiple sclerosis (MS), RCTs are often not feasible because of their size, duration, ethical constraints and costs. Data derived from observational studies complement information provided by RCTs. A major issue is that observational studies are more exposed and prone to biases, which can partly be addressed through rigorous study design or statistical analysis. Propensity score (PS) techniques are the most frequently used. PS is the probability that an individual would receive a certain treatment based on his/her pretreatment characteristics. This score is being widely used in many therapeutic areas and also in MS to adjust for the uncontrolled assignment of treatment in observational studies. However, since PS cannot adjust for unmeasured or unknown confounders, the conclusions from an observational study may not be considered as strong as those from RCTs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878631

Source DB:  PubMed          Journal:  Int MS J        ISSN: 1352-8963


  17 in total

Review 1.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

Review 2.  Utilization of health care databases for pharmacoepidemiology.

Authors:  Yasuo Takahashi; Yayoi Nishida; Satoshi Asai
Journal:  Eur J Clin Pharmacol       Date:  2011-08-02       Impact factor: 2.953

3.  Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Authors:  Luca Prosperini; Francesco Saccà; Cinzia Cordioli; Antonio Cortese; Fabio Buttari; Simona Pontecorvo; Assunta Bianco; Serena Ruggieri; Shalom Haggiag; Vincenzo Brescia Morra; Ruggero Capra; Diego Centonze; Giancarlo Di Battista; Elisabetta Ferraro; Ada Francia; Simonetta Galgani; Claudio Gasperini; Enrico Millefiorini; Massimiliano Mirabella; Carlo Pozzilli
Journal:  J Neurol       Date:  2016-11-22       Impact factor: 4.849

4.  Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.

Authors:  Luca Prosperini; Antonio Cortese; Matteo Lucchini; Laura Boffa; Giovanna Borriello; Maria Chiara Buscarinu; Fioravante Capone; Diego Centonze; Chiara De Fino; Daniela De Pascalis; Roberta Fantozzi; Elisabetta Ferraro; Maria Filippi; Simonetta Galgani; Claudio Gasperini; Shalom Haggiag; Doriana Landi; Girolama Marfia; Giorgia Mataluni; Enrico Millefiorini; Massimiliano Mirabella; Fabrizia Monteleone; Viviana Nociti; Simona Pontecorvo; Silvia Romano; Serena Ruggieri; Marco Salvetti; Carla Tortorella; Silvana Zannino; Giancarlo Di Battista
Journal:  J Neurol       Date:  2019-11-13       Impact factor: 4.849

5.  A Propensity Score Analysis of Homework Adherence-Outcome Relations in Cognitive Behavioral Therapy for Depression.

Authors:  Judith A Callan; Nikolaos Kazantzis; Seo Young Park; Charity G Moore; Michael E Thase; Abu Minhajuddin; Sander Kornblith; Greg J Siegle
Journal:  Behav Ther       Date:  2018-06-05

6.  Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database.

Authors:  Benjamin Garlipp; Henry Ptok; Frank Benedix; Ronny Otto; Felix Popp; Karsten Ridwelski; Ingo Gastinger; Christoph Benckert; Hans Lippert; Christiane Bruns
Journal:  Langenbecks Arch Surg       Date:  2016-11-09       Impact factor: 3.445

7.  Risk adjustment as basis for rational benchmarking: the example of colon carcinoma.

Authors:  Henry Ptok; Frank Marusch; Uwe Schmidt; Ingo Gastinger; Hubertus J C Wenisch; Hans Lippert
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

8.  Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.

Authors:  Benjamin Garlipp; Henry Ptok; Uwe Schmidt; Frank Meyer; Ingo Gastinger; Hans Lippert
Journal:  Langenbecks Arch Surg       Date:  2010-08-15       Impact factor: 3.445

9.  Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Authors:  Tomas Kalincik; Ibrahima Diouf; Sifat Sharmin; Charles Malpas; Tim Spelman; Dana Horakova; Eva Kubala Havrdova; Maria Trojano; Guillermo Izquierdo; Alessandra Lugaresi; Alexandre Prat; Marc Girard; Pierre Duquette; Pierre Grammond; Vilija Jokubaitis; Anneke van der Walt; Francois Grand'Maison; Patrizia Sola; Diana Ferraro; Vahid Shaygannejad; Raed Alroughani; Raymond Hupperts; Murat Terzi; Cavit Boz; Jeannette Lechner-Scott; Eugenio Pucci; Vincent Van Pesch; Franco Granella; Roberto Bergamaschi; Daniele Spitaleri; Mark Slee; Steve Vucic; Radek Ampapa; Pamela McCombe; Cristina Ramo-Tello; Julie Prevost; Javier Olascoaga; Edgardo Cristiano; Michael Barnett; Maria Laura Saladino; Jose Luis Sanchez-Menoyo; Suzanne Hodgkinson; Csilla Rozsa; Stella Hughes; Fraser Moore; Cameron Shaw; Ernest Butler; Olga Skibina; Orla Gray; Allan Kermode; Tunde Csepany; Bhim Singhal; Neil Shuey; Imre Piroska; Bruce Taylor; Magdolna Simo; Carmen-Adella Sirbu; Attila Sas; Helmut Butzkueven
Journal:  Neurology       Date:  2020-12-28       Impact factor: 9.910

10.  Role of oral teriflunomide in the management of multiple sclerosis.

Authors:  Radu Tanasescu; Nikos Evangelou; Cris S Constantinescu
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-22       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.